Sales & Marketing News | pharmaphorum

News

Activist investor Elliott turns its attention to BioMarin

Hedge Fund Elliott Management has bought a big stake in BioMarin Pharma, causing a spike in the company’s share price, and started discussions with the company about its s

News

FTC challenges dozens of ‘improper’ US drug patents

The financial regulator in the US has sent letters to 10 companies that it claims have improperly listed patents in the FDA’s ‘Orange Book’ in order to block generic rival

News

France reported to be probing Sanofi over Dupixent launch

France’s financial prosecutor has reportedly launched an investigation into Sanofi’s “financial communication” surrounding the launch of its biggest-selling drug Dupixent.

News

EFPIA warns EU reforms will hamstring pharma R&D

A trade organisation representing European pharmaceutical companies warned today that the European Commission’s proposed reforms to pharma legislation could result in the

News

Moderna swings to loss as COVID sales slump

Shares in Moderna have been under pressure after the company posted a third-quarter loss of $3.6 billion and a steep fall in COVID-19 vaccine sales, although it still thin

News

Change at the top at BioMarin as CEO Bienaimé steps down

After 18 years in charge, BioMarin Pharma’s chief executive and chairman, Jean-Jacques Bienaimé, has announced his retirement, with a high-powered replacement already line

Activist investor Elliott turns its attention to BioMarin

FTC challenges dozens of ‘improper’ US drug patents

France reported to be probing Sanofi over Dupixent launch

EFPIA warns EU reforms will hamstring pharma R&D

Moderna swings to loss as COVID sales slump

Change at the top at BioMarin as CEO Bienaimé steps down

Altimmune alcohol use disorder drug hits the mark in phase 2

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks